Impact of Cefazolin Co-administration with Vancomycin to Reduce Development of Vancomycin Intermediate Staphylococcus aureus
Development of antimicrobial resistance during monotherapy of complicated methicillin-resistant Staphylococcus aureus bacteremia is problematic due to cross-resistance between vancomycin (VAN) and daptomycin, the only approved agents for this condition. Our objective was to demonstrate that development of resistance under conditions of sub-optimal VAN (200mg q 12h) exposure in S. aureus can be attenuated by addition of cefazolin (CFZ).
Source: Diagnostic Microbiology and Infectious Disease - Category: Microbiology Authors: Nivedita B. Singh, Juwon Yim, Seyedehameneh Jahanbakhsh, George Sakoulas, Michael J. Rybak Source Type: research
More News: Antimicrobial Resistance | Cubicin | Infectious Diseases | Microbiology | MRSA | Staphylococcus Aureus